Renewing the strength behind every heartbeat

Renova Therapeutics is a clinical-stage company developing one-time gene therapies designed to improve cardiac function in patients with heart failure.

Proof Points
  • 56

    patients with HFrEF randomized in a double-blind, placebo-controlled Phase 2 trial of RT-100.

  • JAMA Cardiology

    trial results published in the peer-reviewed Journal of the American Medical Association.

  • Fast Track

    designation granted by FDA for RT-100, reserved for therapies addressing serious conditions with unmet medical need.

The Problem

Today's therapies protect the failing heart, while RT-100 aims to restore its strength

Standard of care

Today

Heart failure affects about 7.7 million American adults.1 Renova is focused on the subpopulation of patients with heart failure with reduced ejection fraction (HFrEF), where roughly 40% die within five years.2

Guideline-directed medical therapy has meaningfully improved survival, but substantial risk remains: once a patient is hospitalized for heart failure, five-year mortality approaches 75%.2 That residual risk is the gap Renova is working to close.

  1. 1 American Heart Association, 2026 Heart Disease and Stroke Statistics Update (7.7 million U.S. adults, 2021–2023 data).
  2. 2 Gorodeski EZ et al. HF STATS 2026: An Updated Report on Heart Failure Epidemiology and Outcomes from the Heart Failure Society of America. Journal of Cardiac Failure, 2026.
Next-generation therapy

Renova's approach (RT-100)

Standard heart failure medicines reduce the burden on a weakened heart, but do not directly target its ability to contract. RT-100 acts on the heart muscle itself, delivering the gene for adenylyl cyclase 6 (AC6), a signaling enzyme diminished in the failing heart, with the aim of improving how it contracts and relaxes.

It's given as a single intracoronary infusion during a standard catheterization, comparable to an angiogram, and is designed to complement guideline-directed medical therapy, not replace it.

How it Works

Restoring how the heart muscle handles calcium

  1. With each beat, heart cells release calcium to contract, and pump it back to relax. In heart failure, a protein called phospholamban brakes that pump, and AC6, which helps hold it in check, declines.

  2. A single intracoronary infusion of RT-100 delivers the AC6 gene to the heart, where cells begin making more of the enzyme.

  3. AC6 reduces both how much phospholamban the cell makes and how active it is. The calcium pump recovers, and the heart contracts and relaxes more effectively.

  4. Drugs that push the heart by raising cAMP have historically worsened outcomes. AC6 improves calcium handling without a sustained rise in cAMP, and the trial showed no increase in arrhythmias.

The science behind RT-100
The Phase 2 Trial

Tested in a randomized, placebo-controlled trial

In a double-blind Phase 2 trial at U.S. medical centers, 56 patients with HFrEF (ejection fraction ≤40%) on guideline-directed therapy were randomized 3:1 to one of five dose levels of RT-100 or placebo and followed for one year.

  • Well tolerated.Similar rates of adverse events in RT-100 and placebo.
  • +8.2Increase in ejection fraction at 12 weeks in non-ischemic patients (subgroup analysis).
  • 67%Fewer heart failure hospitalizations vs. placebo over one year (directional, not statistically significant).

Key findings

Across all patients

At the two highest doses, ejection fraction rose 6 points at four weeks. By twelve weeks that improvement had narrowed to 3 points in the population as a whole and was no longer statistically significant.

Reported in JAMA Cardiology; not shown in figure

Non-ischemic heart failure

Looking by cause of heart failure explained why. In patients whose heart failure was not caused by a prior heart attack — the focus of Renova's next study — ejection fraction rose 8.2 points at twelve weeks versus 0.8 points on placebo (p=0.024), a 28% relative improvement, and the improvement grew between four and twelve weeks. In patients with ischemic heart failure it did not.

Shown in figure below

Ejection fraction change by cause of heart failureChange in ejection fraction from baseline at 4 and 12 weeks. Non-ischemic patients rose to +8.2 points at 12 weeks, ischemic patients ended at −0.8 and placebo at +0.8.1050-5EF ChangeB4w12w+8.2+0.8−0.8
  • Non-ischemic (n=10)
  • Ischemic (n=11)
  • Placebo (n=13)

Anova

  • p=0.024, Non-Ischemic vs Placebo
  • p=0.02, Non-Ischemic vs Ischemic
Ejection fraction change after a single treatment with RT-100 (doses 4 and 5) by cause of heart failure. Non-ischemic n=10, ischemic n=11, placebo n=13. Mean ± SE; ANOVA. Data from Hammond HK et al., JAMA Cardiology 2016, supplementary eFigure.

Hospitalization

Over one year, heart failure hospitalizations were 67% lower in treated patients than in placebo patients (9.5% vs. 28.6%). In a trial of this size, the difference did not reach statistical significance.

Safety

Every patient had an implanted defibrillator, allowing continuous rhythm monitoring. RT-100 produced no increase in arrhythmias, and no myocarditis or liver inflammation.

Relaxation

Catheter measurements showed a statistically significant improvement in the heart muscle's ability to relax at four weeks.

FDA Fast Track designation

RT-100 has received Fast Track designation from the U.S. Food and Drug Administration, a program for investigational therapies that treat serious conditions and have the potential to address an unmet medical need. Fast Track allows more frequent interaction with FDA during development and makes RT-100 eligible for rolling review of a future marketing application and, if relevant criteria are met, for Accelerated Approval and Priority Review.

Pipeline

Two gene therapies for heart failure

RT-100

A one-time gene therapy delivered directly to the heart by intracoronary infusion, for heart failure with reduced ejection fraction (HFrEF). The next study focuses on patients with non-ischemic disease.

Phase 2 completed
Phase 2 completed

RT-100

Ad5.hAC6Single intracoronary administration

Indication

Heart failure with reduced ejection fraction (HFrEF; focus: non-ischemic)

RT-200

A one-time gene therapy given by intravenous injection that enables the body to produce urocortin 2, a naturally occurring peptide with cardiac and metabolic effects. RT-200 is being developed for heart failure with preserved ejection fraction (HFpEF), and preclinical studies suggest potential in type 1 and type 2 diabetes, fatty liver disease (MASLD), and hypertension.

Preclinical
Preclinical

RT-200

AAV8.UCn2Single intravenous injection

Indication

Heart failure with preserved ejection fraction (HFpEF); metabolic disease (diabetes, MASLD, hypertension)

ProgramAssetIndicationStage
RT-100Ad5.hAC6Single intracoronary administrationIndicationHeart failure with reduced ejection fraction (HFrEF; focus: non-ischemic)Phase 2 completed
RT-200AAV8.UCn2Single intravenous injectionIndicationHeart failure with preserved ejection fraction (HFpEF); metabolic disease (diabetes, MASLD, hypertension)Preclinical
What’s Next

Building on
the clinical data

Under new leadership, Renova is preparing RT-100 for the next phase of clinical development.

  1. Phase 2b trial for RT-100

    Preparing a Phase 2b trial of RT-100 in patients with non-ischemic HFrEF.

  2. Manufacturing at commercial scale

    Establishing commercial-scale manufacturing with an experienced gene therapy manufacturing partner.

  3. Advancing RT-200

    Advancing RT-200 toward IND-enabling studies.

Team

  • Alan Horsager, PhD

    President & CEO

    Alan built and led an academic gene therapy lab at USC before serving as CEO of two biotech companies, one exited via acquisition, and leads Renova's strategy, capital formation, and FDA re-engagement.

    LinkedIn of Alan Horsager, PhD
  • Shawn Swaney, CPA

    Chief Financial Officer

    Shawn brings more than 30 years of financial and executive leadership across public and private high-growth companies, including more than $180 million raised and a successful acquisition.

    LinkedIn of Shawn Swaney, CPA
  • H. Kirk Hammond, MD

    Founder; Chair, Scientific Advisory Board; Consultant

    Kirk originated AC6 and urocortin 2 gene transfer, the biology underlying RT-100 and RT-200, assisted by Dr. N. Chin Lai and Dr. Mei Hua Gao. He is Professor of Medicine Emeritus at UC San Diego and a former VA San Diego cardiologist.

    Publications of H. Kirk Hammond, MD
  • Rickey Reinhardt, MD, PhD

    Clinical Development Strategy

    Rickey brings 30 years of drug development experience focused on gene therapy and cardiovascular disease, including as Chief Medical Officer of XyloCor Therapeutics, and leads clinical trial design for RT-100.

    LinkedIn of Rickey Reinhardt, MD, PhD
  • Julie Hagan, MS

    Regulatory Affairs Lead, Strategy & Operations

    Julie brings more than 20 years of global regulatory affairs experience across gene therapy (AAV, CRISPR), cell therapy, RNA/ASO/LNP, and orphan and rare disease programs, and leads Renova's IND and FDA efforts and interactions with Health Authorities.

    LinkedIn of Julie Hagan, MS
  • Marc Semigran, MD

    Cardiology, Clinical and Regulatory Strategy

    Marc led Massachusetts General Hospital's Heart Failure and Cardiac Transplant Program, served as CMO and SVP of MyoKardia through the mavacamten clinical development program, and advises Renova on endpoints and safety.

    LinkedIn of Marc Semigran, MD
FAQ

Frequently
Asked Questions

  • Renova develops gene therapies for heart failure. Our lead program, RT-100, is designed to be given once, through a routine catheter procedure, to improve how the weakened heart muscle works. A second program, RT-200, is in preclinical development.

  • Heart failure doesn't mean the heart has stopped. It means the heart can no longer pump as well as the body needs, which leads to fatigue, shortness of breath, and fluid buildup. It's a chronic condition that usually worsens over time and is one of the most common reasons adults are hospitalized.

  • Most medicines are chemicals or proteins that have to be taken again and again. Gene therapy instead delivers genetic instructions into cells so they can make something useful themselves. Because the cells do the work, a single treatment may have effects that last well beyond the day it's given.

  • Each heartbeat depends on heart muscle cells moving calcium in and out efficiently. In heart failure, that process breaks down, and levels of an enzyme called adenylyl cyclase type 6 (AC6) fall. RT-100 delivers the gene for AC6 to heart muscle cells. The added AC6 eases a natural brake on the cell's calcium pump, helping the heart contract and relax more effectively, without the strain caused by drugs that simply drive the heart harder.

  • Through a catheter procedure similar to the routine angiograms cardiologists perform every day. A thin catheter is advanced from an artery in the wrist to the coronary arteries, and RT-100 is infused. There's no surgery and no injection into the heart muscle itself.

  • In a 56-patient, placebo-controlled trial published in JAMA Cardiology, patients receiving the highest doses showed improved heart function in the weeks after treatment, and fewer were hospitalized for heart failure over the following year than those given placebo. The trial was not large enough to confirm these effects statistically, which is why a larger trial is the next step. No increase in heart rhythm problems was observed.

  • In the Phase 2 trial, patients receiving the highest doses showed improved heart function four weeks after a single treatment, and fewer were hospitalized for heart failure over the following year, though the trial was too small to confirm that difference. Animal studies show AC6 persisting in the heart for months after one treatment, and following patients for longer is a key part of the next clinical study.

  • No. RT-100 is an investigational therapy and has not been approved by the FDA or any other regulatory agency. It's available only within clinical trials.

  • Not at this time. When Renova opens a new study, it will be listed on ClinicalTrials.gov, which is also the best place to find other heart failure trials that are enrolling now.

  • RT-200 takes a different approach. Instead of treating the heart directly, it's given as a single intravenous injection, after which the body's own cells release urocortin 2, a naturally occurring peptide, into the bloodstream. It's being developed for heart failure with preserved ejection fraction and related metabolic diseases, and is currently in preclinical development.

  • Investors and potential partners can reach us through the investor contact form below. Physicians and research centers interested in future RT-100 studies can use the clinical contact form. We're not able to provide medical advice to individual patients.

Contact

Let's talk

I am writing as

Write to our investor team

Financing, licensing, and partnership inquiries. We can share our company overview on request.